| 2026-08-14 | Press release | Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nep |
| 2026-08-13 | Press release | Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates |
| 2026-08-03 | Press release | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-09 | Press release | Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate |
| 2026-07-06 | Press release | Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic |
| 2026-07-01 | Press release | Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences |
| 2026-06-15 | Press release | Fate Therapeutics Appoints Laura Hamill to Board of Directors |
| 2026-06-04 | Press release | Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting |
| 2026-06-02 | Press release | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-01 | Press release | Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting |
| 2026-05-21 | Press release | Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell T |
| 2026-05-13 | Press release | Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates |
| 2026-05-11 | Press release | Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGC |
| 2026-05-05 | Press release | Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program t |
| 2026-05-01 | Press release | Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-30 | Press release | Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Ery |
| 2026-04-16 | Press release | Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for th |
| 2026-04-09 | Press release | Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences |
| 2026-04-02 | Press release | Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-04 | Press release | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-03 | Press release | Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference |
| 2026-02-26 | Press release | Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates |
| 2026-02-03 | Press release | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-05 | Press release | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-12-08 | Press release | Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemi |
| 2025-03-05 | Press release | Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates |
| 2024-11-12 | Press release | Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates |
| 2024-08-13 | Press release | Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates |
| 2024-05-29 | Press release | Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference |
| 2024-03-01 | Press release | Fate Therapeutics to Present at Upcoming March Investor Conferences |
| 2023-08-31 | Press release | Fate Therapeutics to Present at Upcoming September Investor Conferences |
| 2023-05-31 | Press release | Fate Therapeutics to Present at Upcoming June Investor Conferences |
| 2023-03-03 | Press release | Fate Therapeutics to Present at Upcoming March Investor Conferences |